Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNanoco Regulatory News (NANO)

Share Price Information for Nanoco (NANO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 17.00
Bid: 17.00
Ask: 17.94
Change: -0.50 (-2.86%)
Spread: 0.94 (5.529%)
Open: 17.20
High: 17.20
Low: 17.00
Prev. Close: 17.50
NANO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Schedule 1 Update - Evolutec Group plc

29 Apr 2009 17:54

RNS Number : 4161R
AIM
29 April 2009
 



ANNOUNCEMENT TO BE MADE BY THE AIM APPLICANT PRIOR TO ADMISSION IN ACCORDANCE WITH RULE 2 OF THE AIM RULES FOR COMPANIES ("AIM RULES")

COMPANY NAME:

Evolutec Group plc

COMPANY REGISTERED OFFICE ADDRESS AND IF DIFFERENT, COMPANY TRADING ADDRESS (INCLUDING POSTCODES) :

3 More London RiversideLondonSE1 2AQ

COUNTRY OF INCORPORATION:

England & Wales

COMPANY WEBSITE ADDRESS CONTAINING ALL INFORMATION REQUIRED BY AIM RULE 26:

www.evolutec.com

COMPANY BUSINESS (INCLUDING MAIN COUNTRY OF OPERATION) OR, IN THE CASE OF AN INVESTING COMPANY, DETAILS OF ITS INVESTING STRATEGY) IF THE ADMISSION IS SOUGHT AS A RESULT OF A REVERSE TAKE-OVER UNDER RULE 14, THIS SHOULD BE STATED:

Evolutec Group plc ("Evolutec") is classed as an investment company under the AIM Rules. The investment policy of Evolutes' has been to seek a single investment, most probably of a UK or European business, in either the technology, healthcare or service related sectors.

The main country of operation is England.

The boards of Evolutec and Nanoco Tech Public Limited Company ("Nanoco") have reached agreement on the terms of recommended share acquisition by Evolutec of the entire issued and to be issued share capital of Nanoco to be effected by means of a court approved scheme of arrangement. 

Admission is sought as a result of a reverse take-over under Rule 14.

Nanoco is a leading nanotechnology company involved in the development and manufacture of fluorescent semi-conducting materials called quantum dots. Quantum dots are a platform technology with uses in a wide range of applications from life sciences through to optoeletronics dominated by solid state lighting, photovoltaics and next generation displays.

Quantum dot based applications have the ability to potentially offer significant benefits in performance and energy savings compared to those materials currently used.

DETAILS OF SECURITIES TO BE ADMITTED INCLUDING ANY RESTRICTIONS AS TO TRANSFER OF THE SECURITIES (i.e. where known, number and type of shares, nominal value and issue price to which it seeks admission and the number and type to be held as treasury shares):

184,088,032 Ordinary Shares of 10p each

CAPITAL TO BE RAISED ON ADMISSION (IF APPLICABLEAND ANTICIPATED MARKET CAPITALISATION ON ADMISSION:

Anticipated market capitalisation upon admission - £69,033,012

PERCENTAGE OF AIM SECURITIES NOT IN PUBLIC HANDS AT ADMISSION:

83.56%

DETAILS OF ANY OTHER EXCHANGE OR TRADING PLATFORM TO WHICH THE AIM SECURITIES (OR OTHER SECURITIES OF THE COMPANY) ARE OR WILL BE ADMITTED OR TRADED:

N/A

FULL NAMES AND FUNCTIONS OF DIRECTORS AND PROPOSED DIRECTORS (underlining the first name by which each is known or including any other name by which each is known):

Directors

Dr. David Philip Bloxham - Non-Executive Chairman

Gordon James Hall - Non-Executive Director

Mark Barrie Hawtin - Non-Executive Director

Graeme Manson Hart - Non-Executive Director

Proposed Directors

Dr. Peter John Rowley - Non-Executive Chairman

Dr. Michael Albert Edelman - Chief Executive Officer

Dr. Nigel Leroy Pickett - Chief Technical Officer

Michael Anthony Bretherton - Chief Financial Officer

Upon Admission the board of the Company will comprise of the Proposed Directors and Gordon James Hall.

FULL NAMES AND HOLDINGS OF SIGNIFICANT SHAREHOLDERS EXPRESSED AS A PERCENTAGE OF THE ISSUED SHARE CAPITAL, BEFORE AND AFTER ADMISSION (underlining the first name by which each is known or including any other name by which each is known):

Before Admission

Gartmore Investment Management Limited - 25.99%

Kisco Limited - 12.16%

Fortis Bank - 11.06%

GAM International - 10.87%

Close Asset Management - 5.07%

Charles Stanley - 4.24%

After Admission

ORA Guernsey - 36.34%

Gartmore - 16.10%

Mitsubishi UFJ - 6.45%

Nigel Pickett - 5.67%

Paul O'Brien - 5.39%

Michael Edelman - 5.03%

Manchester Tech Fund - 3.73%

Nora Powell - 3.26%

NAMES OF ALL PERSONS TO BE DISCLOSED IN ACCORDANCE WITH SCHEDULE 2, PARAGRAPH (H) OF THE AIM RULES:

None

ANTICIPATED ACCOUNTING REFERENCE DATE 

DATE TO WHICH THE MAIN FINANCIAL INFORMATION IN THE ADMISSION DOCUMENT HAS BEEN PREPARED (this may be represented by unaudited interim financial information)

DATES BY WHICH IT MUST PUBLISH ITS FIRST THREE REPORTS PURSUANT TO AIM RULES 18 AND 19:

31 July

Year ended 31 December 2008.

30 November 2009 (Annual Accounts) 30 April 2010 (Interims) 31 January 2011 (Annual Report)

Note: The current accounting reference date is 31 December and will change on Admission to 31 July.

EXPECTED ADMISSION DATE:

1 May 2009

NAME AND ADDRESS OF NOMINATED ADVISER:

Zeus Capital Limited

3 Ralli Courts

West Riverside

Manchester

M3 5FT

NAME AND ADDRESS OF BROKER:

Zeus Capital Limited

3 Ralli Courts

West Riverside

Manchester

M3 5FT

OTHER THAN IN THE CASE OF A QUOTED APPLICANTDETAILS OF WHERE (POSTAL OR INTERNET ADDRESS) THE ADMISSION DOCUMENT WILL BE AVAILABLE FROM, WITH A STATEMENT THAT THIS WILL CONTAIN FULL DETAILS ABOUT THE APPLICANT AND THE ADMISSION OF ITS SECURITIES:

The Admission document will be available from the following address and will contain full details about the applicant and the admission of its securities;

Zeus Capital Limited

3 Ralli Courts

West Riverside

Manchester

M3 5FT

DATE OF NOTIFICATION:

29 April 2009

NEW/ UPDATE:

Update

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
PAAUKVNRKORSUAR
Date   Source Headline
8th Oct 20211:48 pmRNSNotice of Results
19th Aug 20217:00 amRNSNon-Executive Director Appointment
16th Jul 20214:41 pmRNSSecond Price Monitoring Extn
16th Jul 20214:35 pmRNSPrice Monitoring Extension
15th Jul 20217:00 amRNSNon-dilutive loan note subscription
5th Jul 20217:30 amRNSDevelopment Agreement
28th Jun 20217:00 amRNSLitigation update and non-dilutive debt facility
10th Jun 202111:33 amRNSBlocklisting Six-Monthly Return
24th May 202112:20 pmRNSHolding(s) in Company
20th May 20217:00 amRNSLitigation Update
13th May 20217:00 amRNSProject Extension
12th May 20217:00 amRNSLitigation Update
6th May 20213:28 pmRNSHolding(s) in Company
30th Mar 20217:00 amRNSInterim Results
29th Mar 20217:00 amRNSLitigation Update
26th Mar 20214:41 pmRNSSecond Price Monitoring Extn
26th Mar 20214:36 pmRNSPrice Monitoring Extension
24th Mar 20213:36 pmRNSAmendment to Executive Director Service Terms
16th Mar 20212:30 pmRNSNotice of Results
10th Feb 20214:40 pmRNSSecond Price Monitoring Extn
10th Feb 20214:35 pmRNSPrice Monitoring Extension
25th Jan 20214:41 pmRNSSecond Price Monitoring Extn
25th Jan 20214:35 pmRNSPrice Monitoring Extension
29th Dec 20204:41 pmRNSSecond Price Monitoring Extn
29th Dec 20204:36 pmRNSPrice Monitoring Extension
21st Dec 20207:00 amRNSDirector/PDMR Shareholding
11th Dec 202011:40 amRNSBlocklisting Six-Monthly Return
3rd Dec 202012:10 pmRNSResult of AGM
3rd Dec 20207:00 amRNSAGM Statement
25th Nov 20207:00 amRNSGrant Funding Award for Life Sciences Project
17th Nov 20205:50 pmRNS2020 Annual Report and Notice of AGM
22nd Oct 20204:40 pmRNSSecond Price Monitoring Extn
22nd Oct 20204:35 pmRNSPrice Monitoring Extension
21st Oct 20203:16 pmRNSDirector/PDMR Shareholding
13th Oct 20207:00 amRNSPreliminary Results
7th Oct 20207:00 amRNSNotice of Results
25th Sep 20204:36 pmRNSPrice Monitoring Extension
1st Sep 20207:00 amRNSDirectorate Changes
21st Jul 202011:25 amRNSHolding(s) in Company
20th Jul 202012:35 pmRNSHolding(s) in Company
16th Jul 20202:15 pmRNSDirector/PDMR Shareholding
16th Jul 20207:00 amRNSResult of Fund Raise
15th Jul 20205:20 pmRNSPrimaryBid.com Offer
15th Jul 20205:17 pmRNSTrading Update and Proposed Fundraising
14th Jul 20209:55 amRNSHolding(s) in Company
13th Jul 20207:00 amRNSLitigation Funding Agreement
2nd Jul 20204:40 pmRNSSecond Price Monitoring Extn
2nd Jul 20204:36 pmRNSPrice Monitoring Extension
30th Jun 202010:06 amRNSHolding(s) in Company
9th Jun 20207:00 amRNSBlocklisting Six-Monthly Return

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.